Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore

11 Feb 2022

Abstract excerpt

10.1001/jama.2022.1922

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Vaccine Coverage and Hesitancy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35147657
DOI: 10.1001/jama.2022.1922

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in SingaporePMID 35147657Read ↗

Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in ThailandSemantic proximity Read ↗

Waning vaccine response to severe COVID-19 outcomes during omicron predominance in ThailandSemantic proximity Read ↗

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 MonthsSemantic proximity Read ↗

Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in EnglandSemantic proximity Read ↗

Evaluation of the Safety and Immunogenicity of Different COVID-19 Vaccine Combinations in Healthy Individuals: Study Protocol for a Randomized, Subject-blinded, Controlled Phase 3 Trial [PRIBIVAC]Semantic proximity Read ↗

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccineSemantic proximity Read ↗

Heterologous third and fourth dose vaccine to reduce severity and mortality in COVID-19 patients during delta and omicron predominance: A cohort study in Chiang Mai, ThailandSemantic proximity Read ↗

Reported Effectiveness of COVID-19 Booster Vaccines: A Systematic Review of Early Literature and Implications for Emerging Vaccination PolicySemantic proximity Read ↗

Incidence and Nature of Adverse Events Following COVID-19 Second Boosters: Insights from Taiwan's Universal Vaccination StrategySemantic proximity Read ↗

Vaccine efficacy against COVID-19: A foresight on the host-associated factorsSemantic proximity Read ↗

Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population; A systematic review and meta-analysisSemantic proximity Read ↗

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.